颅内生殖细胞肿瘤的药物治疗

doi:10.16352/j.issn.1001-6325.2024.10.1350

摘要/Abstract

摘要： 颅内生殖细胞肿瘤(IGCT)为一种罕见的脑肿瘤,男性青少年患者最为常见。组织学上可分为生殖细胞瘤、成熟畸胎瘤、未成熟畸胎瘤、伴体细胞型恶性的畸胎瘤(teratoma with somatic-type malignancy)、胚胎癌、卵黄囊瘤、绒毛膜癌和混合型颅内生殖细胞肿瘤。由于传统的大剂量放疗可导致包括神经认知障碍及激素分泌障碍等各种长期不良反应,影响生活质量,故药物治疗的地位逐渐提高。药物选择方面,化疗仍为目前最常用的治疗手段,近年来随着靶向治疗及免疫治疗的发展,各种新型药物亦逐渐走进人们的视野。

关键词: 颅内生殖细胞肿瘤, 化疗, 靶向治疗, 免疫治疗

Abstract: Intracranial germ cell tumor (IGCT) is an uncommon brain tumor, which is mostly found in male adolescents. The histology of IGCT can be divided into germinoma, mature teratoma, immature teratoma, teratoma with somatic-type malignancy, embryonic carcinoma, yolk sac tumor, choriocarcinoma and mixed intracranial germ cell tumor. Since classic high-dose radiotherapy can lead to a variety of long-term adverse effects including neurocognitive disorders and hormone secretion disorders, affecting the quality of life, chemotherapy with anti-tumor drugs is gradually increasing and clinicians have faced to more choices in the field of drug selection.

Key words: intracranial germ cell tumor, chemotherapy, targeted therapy, immunotherapy

中图分类号:

刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.

参考文献 54

[1]	Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019[J]. Neuro Oncol, 2022, 24: v1-v95.
[2]	Narita Y, Shibui S. Trends and outcomes in the treatment of gliomas based on data during 2001—2004 from the Brain Tumor Registry of Japan[J]. Neurol Med Chir (Tokyo), 2015, 55: 286-295.
[3]	McCarthy BJ, Shibui S, Kayama T,et al. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries[J]. Neuro Oncol, 2012, 14: 1194-1200.
[4]	Cappellano AM, Dassi N, Mançano B, et al. Outcome of children and adolescents with primary intracranial germinoma treated with chemotherapy and reduced dose-field irradiation: a prospective Brazilian experience[J]. JCO Glob Oncol, 2023, 9: e2200257. doi: 10.1200/GO.22.00257.
[5]	Report of Japan neurosurgery registry (2015—2017)[J]. Neurol Med Chir (Tokyo), 2019, 59: 13-81.
[6]	Lee SH, Jung KW, Ha J, et al. Nationwide population-based incidence and survival rates of malignant central nervous system germ cell tumors in Korea, 2005—2012[J]. Cancer Res Treat, 2017, 49: 494-501.
[7]	杨桥, 颅内生殖细胞肿瘤的治疗进展[J]. 中国肿瘤临床, 2020, 47: 590-594.
[8]	Wei XH, Shen HC, Tang SX, et al. Radiologic features of primary intracranial ectopic germinomas: case reports and literature review[J]. Medicine (Baltimore), 2016, 95: e5543. doi:10.1097/MD.0000000000005543.
[9]	Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23: 1231-1251.
[10]	Aoyama H, Shirato H, Kakuto Y, et al. Pathologically-proven intracranial germinoma treated with radiation therapy[J]. Radiother Oncol, 1998, 47: 201-205.
[11]	Stavinoha PL, Askins MA, Powell SK, et al. Neurocognitive and psychosocial outcomes in pediatric brain tumor survivors[J]. Bioengineering (Basel), 2018, 5. doi: 10.3390/bioengineering5030073.
[12]	Oka H, Kawano N, Tanaka T, et al. Long-term functional outcome of suprasellar germinomas: usefulness and limitations of radiotherapy[J]. J Neurooncol, 1998, 40: 185-190.
[13]	Kobayashi T, Yoshida J, Ishiyama J, et al. Combination chemotherapy with cisplatin and etoposide for malignant intracranial germ-cell tumors. An experimental and clinical study[J]. J Neurosurg, 1989, 70: 676-681.
[14]	董晓书, 杨建, 韩一芃, 等. 儿童颅内原发性非生殖细胞瘤性恶性生殖细胞肿瘤的治疗及预后[J]. 中华神经外科杂志, 2019, 35: 776-781.
[15]	Frappaz D, Dhall G, Murray MJ, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults[J]. Neuro Oncol, 2022, 24: 516-527.
[16]	Fu H, Guo X, Li R, et al. Radiotherapy and chemother-apy plus radiation in the treatment of patients with pure intracranial germinoma: a meta-analysis[J]. J Clin Neurosci, 2017, 43: 32-38.
[17]	Fouladi M, Grant R, Baruchel S, et al. Comparison of survival outcomes in patients with intracranial germinomas treated with radiation alone versus reduced-dose radiation and chemotherapy[J]. Childs Nerv Syst, 1998, 14: 596-601.
[18]	Zschäbitz S, Lasitschka F, Hadaschik B, et al. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation[J]. Eur J Cancer, 2017, 76: 1-7.
[19]	Huang PI, Chen YW, Wong TT, et al. Extended focal radiotherapy of 30 Gy alone for intracranial synchronous bifocal germinoma: a single institute experience[J]. Childs Nerv Syst, 2008, 24: 1315-1321.
[20]	Khatua S, Dhall G, O′Neil S, et al. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation[J]. Pediatr Blood Cancer, 2010, 55: 42-46.
[21]	Aoyama H, Shirato H, Ikeda J, et al. Induction chemotherapy followed by low-dose involved-field radiotherapy for intracranial germ cell tumors[J]. J Clin Oncol, 2002, 20: 857-865.
[22]	Shimizu H, Motomura K, Ohka F, et al. Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study[J]. J Neurosurg, 2020, 135: 449-457
[23]	Afzal S, Wherrett D, Bartels U, et al. Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy[J]. J Neurooncol, 2010, 97: 393-399.
[24]	Wong J, Goddard K, Laperriere N, et al. Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults[J]. J Neurooncol, 2020, 149: 523-532.
[25]	Calaminus G, Kortmann R, Worch J, et al. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease[J]. Neuro Oncol, 2013, 15: 788-796.
[26]	da Silva NS, Cappellano AM, Diez B, et al. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study[J]. Pediatr Blood Cancer, 2010, 54: 377-383.
[27]	Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The first international central nervous system germ cell tumor study[J]. J Clin Oncol, 1996, 14: 2908-2915.
[28]	Kellie SJ, Boyce H, Dunkel IJ, et al. Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach. Pediatr Blood Cancer[J], 2004, 43: 126-133.
[29]	Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases[J]. J Neurosurg, 1997, 86: 446-455.
[30]	Takami H, Fukuoka K, Fukushima S, et al. Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT consortium[J]. Neuro Oncol, 2019, 21: 1565-1577.
[31]	Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial[J]. Neuro Oncol, 2017, 19: 1661-1672.
[32]	Calaminus G, Andreussi L, Garré ML, et al. Secreting germ cell tumors of the central nervous system (CNS). First results of the cooperative German/Italian pilot study (CNS sGCT)[J]. Klin Padiatr, 1997, 20: 222-227.
[33]	Goldman S, Bouffet E, Fisher PG, et al. Phase Ⅱ trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a children's oncology group study[J]. J Clin Oncol, 2015, 33: 2464-2471.
[34]	Bowzyk Al-Naeeb A, Murray M, Horan G, et al. Current management of intracranial germ Cell tumours[J]. Clin Oncol (R Coll Radiol), 2018, 30: 204-214.
[35]	Abu Arja MH, Stanek JR, Finlay JL, et al. Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors[J]. Childs Nerv Syst, 2018, 34: 2179-2186.
[36]	Perez-Somarriba M, Moreno-Tejero ML, Rozas MI, et al. Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors[J]. Pediatr Blood Cancer, 2020, 67: e28089. doi: 10.1002/pbc.28089.
[37]	Wang L, Yamaguchi S, Burstein MD, et al. Novel somatic and germline mutations in intracranial germ cell tumours[J]. Nature, 2014, 511: 241-245.
[38]	Fukushima S, Yamashita S, Kobayashi H, et al. Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas[J]. Acta Neuropathol, 2017, 133:445-462.
[39]	Ichimura K, Fukushima S, Totoki Y, et al. Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy[J]. Acta Neuropathologica, 2016, 131: 889-901.
[40]	Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/german testicular cancer study group cooperative study[J]. Ann Oncol, 2011, 22: 2654-2660.
[41]	Wanggou S, Jiang X, Li Q, et al. HESRG: a novel biomarker for intracranial germinoma and embryonal carcinoma[J]. J Neurooncol, 2012, 106: 251-259.
[42]	Taylor-Weiner A, Zack T, O′Donnell E, et al. Genomic evolution and chemoresistance in germ-cell tumours[J]. Nature, 2016, 540: 114-118.
[43]	Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond[J]. Clin Dermatol, 2013, 31: 191-199.
[44]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373: 123-135.
[45]	Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12: 252-264.
[46]	Brahmer JR, Drake CG, Wollner I, et al. Phase Ⅰ study of single-agent anti-programmed death-1(MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28: 3167-3175.
[47]	Liu B, Arakawa Y, Yokogawa R, et al. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes[J]. PLoS One, 2018, 13: e0194594. doi: 10.1371/journal.pone.0194594.
[48]	Wildeman ME, Shepard MJ, Oldfield EH, et al. Central nervous system germinomas express programmed death ligand 1[J]. J Neuropathol Exp Neurol, 2018, 77: 312-316.
[49]	Takami H, Fukushima S, Aoki K, et al. Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance[J]. Neuropathol Appl Neurobiol, 2020, 46: 111-124.
[50]	Nishimoto M, Ohara K, Kamamoto D, et al. Tumor immune microenvironment is associated with the growth of intracranial germinomas[J]. J Neurooncol, 2020, 146: 139-146.
[51]	Woods JK, Lidov HG, Ligon KL, et al. PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors[J]. Mod Pathol, 2022, 35: 1770-1774.
[52]	Fankhauser CD, Curioni-Fontecedro A, Allmann V, et al. Frequent PD-L1 expression in testicular germ cell tumors[J]. Br J Cancer, 2015, 113: 411-443.
[53]	Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor(PD-1) and its ligand 1(PD-L1) in testicular germ cell tumors[J]. Ann Oncol, 2016, 27: 300-305.
[54]	Osada T, Fujimaki T, Takamizawa M, et al. Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report[J]. Jpn J Clin Oncol, 2001, 31: 403-406.